Here's how phar­ma com­pa­nies might re­move their prod­ucts from price ne­go­ti­a­tion

Sev­er­al of the drugs on the list of 10 that will face price ne­go­ti­a­tions may not ac­tu­al­ly end up on the list, thanks to up­com­ing gener­ic and biosim­i­lar com­pe­ti­tion or tac­tics that com­pa­nies may use to speed com­pe­ti­tion.

Of the 10 drugs on CMS’ list, at least four so far —John­son & John­son’s Ste­lara, No­var­tis’ En­tresto, Am­gen’s En­brel and No­vo Nordisk’s in­sulins — may not see ne­go­ti­a­tions in 2026 due to in­com­ing gener­ic or biosim­i­lar com­pe­ti­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER